BRISTOL-MYERS SQUIBB COMPANY Restructuring and Related Cost, Cost Incurred to Date
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Restructuring and Related Cost, Cost Incurred to Date of $1.30 billion as of 2019-09-30, per its 10-Q filed 2019-10-31.
Discontinued › Notes › Restructuring and Related Activities › Restructuring and Related Cost, Expected Cost
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2019-10-31
- 2019-09-30: Restructuring and Related Cost, Cost Incurred to Date $1.30B.
- 2019-06-30: Restructuring and Related Cost, Cost Incurred to Date $1.30B.
- 2019-03-31: Restructuring and Related Cost, Cost Incurred to Date $1.10B.
- 2018-12-31: Restructuring and Related Cost, Cost Incurred to Date $1.10B.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2019-09-30 | $1.30B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $1.30B 10-Q · filed 2019-07-25 |
| 2019-03-31 | $1.10B 10-Q · filed 2019-04-25 |
| 2018-12-31 | $1.10B 10-K · filed 2019-02-25 |
| 2017-12-31 | $800.00M 10-K · filed 2018-02-13 |
| 2016-12-31 | $90.00M 10-K · filed 2017-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |